Bard buys bulking agent from Genyx
This article was originally published in Clinica
Executive Summary
CR Bard has exercised its right to acquire a PMA-approved implantable bulking agent for the treatment of stress urinary incontinence. The Murray Hill, New Jersey firm intends to launch Uryx, which it acquired from Genyx Medical, in the first half of 2005. The polymer product is minimally invasively injected into the area around the urethra.